Colao A, Grasso LFS, Giustina A, Melmed S, Chanson P, Pereira AM, Pivonello R (2019) Acromegaly. Nat Rev Dis Primers 5(1):20. https://doi.org/10.1038/s41572-019-0071-6

Article  PubMed  Google Scholar 

Melmed S, Kaiser UB, Lopes MB, Bertherat J, Syro LV, Raverot G, Reincke M, Johannsson G, Beckers A, Fleseriu M, Giustina A, Wass JAH, Ho KKY (2022) Clinical Biology of the Pituitary Adenoma. Endocr Rev 43(6):1003–1037. https://doi.org/10.1210/endrev/bnac010

Article  PubMed  PubMed Central  Google Scholar 

Giustina A, Boni E, Romanelli G, Grassi V, Giustina G (1995) Cardiopulmonary performance during exercise in acromegaly, and the effects of acute suppression of growth hormone hypersecretion with octreotide. Am J Cardiol 75(15):1042–1047. https://doi.org/10.1016/s0002-9149(99)80721-8

Article  CAS  PubMed  Google Scholar 

Giustina A, Barkan A, Beckers A, Biermasz N, Biller BMK, Boguszewski C, Bolanowski M, Bonert V, Bronstein MD, Casanueva FF, Clemmons D, Colao A, Ferone D, Fleseriu M, Frara S, Gadelha MR, Ghigo E, Gurnell M, Heaney AP, Ho K, Ioachimescu A, Katznelson L, Kelestimur F, Kopchick J, Krsek M, Lamberts S, Losa M, Luger A, Maffei P, Marazuela M, Mazziotti G, Mercado M, Mortini P, Neggers S, Pereira AM, Petersenn S, Puig-Domingo M, Salvatori R, Shimon I, Strasburger C, Tsagarakis S, van der Lely AJ, Wass J, Zatelli MC, Melmed S (2020) A Consensus on the diagnosis and treatment of Acromegaly comorbidities: an update. J Clin Endocrinol Metab 105(4). https://doi.org/10.1210/clinem/dgz096

Esposito D, Ragnarsson O, Johannsson G, Olsson DS (2020) Prolonged diagnostic delay in acromegaly is associated with increased morbidity and mortality. Eur J Endocrinol/Eur Fed Endocr Soc 182(6):523–531. https://doi.org/10.1530/EJE-20-0019

Article  CAS  Google Scholar 

Giustina A, Biermasz N, Casanueva FF, Fleseriu M, Mortini P, Strasburger C, van der Lely AJ, Wass J, Melmed S (2024) Consensus on criteria for acromegaly diagnosis and remission. Pituitary 27(1):7–22. https://doi.org/10.1007/s11102-023-01360-1

Article  CAS  PubMed  Google Scholar 

Davi MV, Dalle Carbonare L, Giustina A, Ferrari M, Frigo A, Lo Cascio V, Francia G (2008) Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease. Eur J Endocrinol/Eur Fed Endocr Soc 159(5):533–540. https://doi.org/10.1530/EJE-08-0442

Article  CAS  Google Scholar 

Vandeva S, Yaneva M, Natchev E, Elenkova A, Kalinov K, Zacharieva S (2015) Disease control and treatment modalities have impact on quality of life in acromegaly evaluated by Acromegaly Quality of Life (AcroQoL) Questionnaire. Endocrine 49(3):774–782. https://doi.org/10.1007/s12020-014-0521-6

Article  CAS  PubMed  Google Scholar 

Crespo I, Valassi E, Webb SM (2017) Update on quality of life in patients with acromegaly. Pituitary 20(1):185–188. https://doi.org/10.1007/s11102-016-0761-y

Article  PubMed  Google Scholar 

Mazziotti G, Maffezzoni F, Frara S, Giustina A (2017) Acromegalic osteopathy. Pituitary 20(1):63–69. https://doi.org/10.1007/s11102-016-0758-6

Article  CAS  PubMed  Google Scholar 

Mazziotti G, Frara S, Giustina A (2018) Pituitary diseases and Bone. Endocr Rev 39(4):440–488. https://doi.org/10.1210/er.2018-00005

Article  PubMed  Google Scholar 

Giustina A, Mazziotti G, Canalis E (2008) Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev 29(5):535–559. https://doi.org/10.1210/er.2007-0036

Article  CAS  PubMed  PubMed Central  Google Scholar 

Giustina A, Bussi AR, Jacobello C, Wehrenberg WB (1995) Effects of recombinant human growth hormone (GH) on bone and intermediary metabolism in patients receiving chronic glucocorticoid treatment with suppressed endogenous GH response to GH-releasing hormone. J Clin Endocrinol Metab 80(1):122–129. https://doi.org/10.1210/jcem.80.1.7829600

Article  CAS  PubMed  Google Scholar 

Canalis E, Giustina A, Bilezikian JP (2007) Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 357(9):905–916. https://doi.org/10.1056/NEJMra067395

Article  CAS  PubMed  Google Scholar 

Ueland T, Fougner SL, Godang K, Schreiner T, Bollerslev J (2006) Serum GH and IGF-I are significant determinants of bone turnover but not bone mineral density in active acromegaly: a prospective study of more than 70 consecutive patients. Eur J Endocrinol/Eur Fed Endocr Soc 155(5):709–715. https://doi.org/10.1530/eje.1.02285

Article  CAS  Google Scholar 

Szulc P (2020) Biochemical bone turnover markers in hormonal disorders in adults: a narrative review. J Endocrinol Invest 43(10):1409–1427. https://doi.org/10.1007/s40618-020-01269-7

Article  CAS  Google Scholar 

Mazziotti G, Biagioli E, Maffezzoni F, Spinello M, Serra V, Maroldi R, Floriani I, Giustina A (2015) Bone turnover, bone mineral density, and fracture risk in acromegaly: a meta-analysis. J Clin Endocrinol Metab 100(2):384–394. https://doi.org/10.1210/jc.2014-2937

Article  CAS  PubMed  Google Scholar 

Mazziotti G, Marzullo P, Doga M, Aimaretti G, Giustina A (2015) Growth hormone deficiency in treated acromegaly. Trends Endocrinol Metab 26(1):11–21. https://doi.org/10.1016/j.tem.2014.10.005

Article  CAS  PubMed  Google Scholar 

Dincel AS, Jorgensen NR, Metabolism I-IJCoB (2023) New Emerging biomarkers for bone disease: Sclerostin and Dickkopf-1 (DKK1). Calcif Tissue Int 112(2):243–257. https://doi.org/10.1007/s00223-022-01020-9

Article  CAS  PubMed  Google Scholar 

Silva PPB, Pereira RMR, Takayama L, Borba CG, Duarte FH, Trarbach EB, Martin RM, Bronstein MD, Tritos NA, Jallad RS (2021) Impaired bone microarchitecture in Premenopausal Women with Acromegaly: the possible role of wnt signaling. J Clin Endocrinol Metab 106(9):2690–2706. https://doi.org/10.1210/clinem/dgab260

Article  PubMed  Google Scholar 

Pekkolay Z, Kilinc F, Gozel N, Onalan E, Tuzcu AK (2020) Increased serum sclerostin levels in patients with active acromegaly. J Clin Endocrinol Metab 105(3). https://doi.org/10.1210/clinem/dgz254

Chen H, Huang H, Wang Y, Zhang Y, Liu M, Lou Y, Zhang Z, Zhu D, Li P (2022) Decreased serum wnt antagonist levels in patients with active acromegaly. Endocr Practice: Official J Am Coll Endocrinol Am Association Clin Endocrinologists 28(5):515–520. https://doi.org/10.1016/j.eprac.2022.01.011

Article  Google Scholar 

Uygur MM, Yazici DD, Bugdayci O, Yavuz DG (2021) Prevalence of vertebral fractures and serum sclerostin levels in acromegaly. Endocrine 73(3):667–673. https://doi.org/10.1007/s12020-021-02751-9

Article  CAS  PubMed  Google Scholar 

Claessen K, Pelsma ICM, Kroon HM, van Lierop AH, Pereira AM, Biermasz NR, Appelman-Dijkstra NM (2022) Low sclerostin levels after long-term remission of acromegaly. Endocrine 75(1):228–238. https://doi.org/10.1007/s12020-021-02850-7

Article  CAS  PubMed  Google Scholar 

Belaya Z, Grebennikova T, Melnichenko G, Nikitin A, Solodovnikov A, Brovkina O, Grigoriev A, Rozhinskaya L, Lutsenko A, Dedov I (2018) Effects of active acromegaly on bone mRNA and microRNA expression patterns. Eur J Endocrinol/Eur Fed Endocr Soc 178(4):353–364. https://doi.org/10.1530/EJE-17-0772

Article  CAS  Google Scholar 

Kamenicky P, Mazziotti G, Lombes M, Giustina A, Chanson P (2014) Growth hormone, insulin-like growth factor-1, and the kidney: pathophysiological and clinical implications. Endocr Rev 35(2):234–281. https://doi.org/10.1210/er.2013-1071

Article  CAS  PubMed  Google Scholar 

Constantin T, Tangpricha V, Shah R, Oyesiku NM, Ioachimescu OC, Ritchie J, Ioachimescu AG (2017) Calcium and bone turnover markers in Acromegaly: a prospective, controlled study. J Clin Endocrinol Metab 102(7):2416–2424. https://doi.org/10.1210/jc.2016-3693

Article  PubMed  Google Scholar 

Giustina A, Lazaretti-Castro M, Martineau AR, Mason RS, Rosen CJ, Schoenmakers I (2024) A view on vitamin D: a pleiotropic factor? Nat Rev Endocrinol 20(4):202–208. https://doi.org/10.1038/s41574-023-00942-0

Article  CAS  PubMed  Google Scholar 

Giustina A (2024) Vitamin D at the crossroad of prediabetes, Sarcopenia, and risk of falls. Lancet Healthy Longev 5(4):e239–e240. https://doi.org/10.1016/S2666-7568(24)00032-1

Article  PubMed  Google Scholar 

Povaliaeva AA, Bogdanov VP, Zhukov AY, Pigarova EA, Dzeranova LK, Rozhinskaya LY, Mel’nichenko GA, Mokrysheva NG (2022) Characterization of vitamin D metabolism in active acromegaly in the setting of bolus (150,000 IU) cholecalciferol treatment. Endocrine 76(2):407–418. https://doi.org/10.1007/s12020-022-02994-0

Article  CAS  PubMed